| Previous close | 91.59 |
| Open | 91.59 |
| Bid | 98.10 |
| Ask | 103.80 |
| Strike | 290.00 |
| Expiry date | 2024-01-19 |
| Day's range | 69.90 - 91.59 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksMyriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up
Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina.
GlobeNewswireMyriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera
Motley FoolIs the Worst Over for Illumina Stock?
With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business, shareholders are doubtlessly wondering whether the stock's decline is finished, or if it's just getting started. With the naming of a new chief technology officer (CTO) on August 9 and a new CEO on September 5, at a minimum investors can have confidence that something about the company's strategy is going to change. The new CEO will take over on September 25, which, in conjunction with the new CTO, will help Illumina break with the management team responsible for its acquisition of Grail, a cancer testing business.
